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Two frequent single-nucleotide-polymorphisms (SNPs) are present in the indoleamine 2,3-dioxygenase 2 (IDO2) gene
that influence its enzymatic activity. Thus, one SNP (R248W) is associated with a reduction in IDO2 catalytic activity,
whereas the other SNP (Y359stop) generates a premature stop codon abolishing activity completely. In the present
study, we describe the presence of a specific cellular immune response in the periphery which correlated with the
functional status of the IDO2 protein. Hence, the induction of IDO2-specific T cells in peripheral blood requires the
presence of a functional IDO2 protein and, consequently, is restricted to individuals that are not homozygous for the stop
codon. Furthermore, we detected stronger T-cell responses in donors with the homozygous Y wild type at position 359
when compared with the heterozygous genotype. Interestingly, we found a higher number of immune responses against
IDO2 in patients homozygous for the 248W giving reduction in IDO2 activity compared with the 248R. Hence,
spontaneous immune responses against IDO2 seem to be correlated with reduced enzymatic activity of IDO2. The
patient IDO2 genotype may well influence the outcome of IDO2-based anti-cancer vaccination.
Introduction
Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory
enzyme that can foster an immunotolerant environment. Hence,
IDO has been implicated in suppressing T-cell immunity in
normal and pathological settings, including cancer.
1 Several
studies have shown that indoleamine 2,3-dioxygenase (IDO)
functions in facilitating conversion of naïve T lymphocytes into T
regulatory cells.
2 Consistent with a role for IDO in mediating
tolerance to tumor, preclinical studies have shown the promise
of IDO inhibitors in targeting several cancers.
3-7 Especially,
1-methyl-tryptophan (1MT) has been widely studied as an
inhibitor of IDO activity. Interestingly, recent studies have
shown that the racemer D-1MT has superior antitumor activity
compared with L-1MT.
8 The D-1MT preferentially target a
paralog of IDO named indoleamine 2,3-dioxygenase-2 (IDO2).
9
Several lines of data have suggested a possible link between the
IDO-like protein IDO2 and cancer. First, IDO2 expression has
been described in human tumors, including renal and pancreatic
tumors. In pancreatic tumors IDO2 expression was described
both at the level of the tumor cell as well as immune cells in
tumor-draining lymph nodes.
10 Second, the apparent selective
inhibition of IDO2 by the D stereoisomer of the IDO blocker
1MT, which tends to be more active than the L-isomer in a
variety of biological assays for IDO function, suggests that IDO2
may be important to sustain immune escape and growth of
tumors.
8 Especially, D-1MT heighten chemotherapeutic efficacy
in mouse models of cancer in a nontoxic fashion.
Two frequent single-nucleotide-polymorphisms (SNPs) have
been revealed in the IDO2 gene. Thus, one SNP (R248W) was
associated with a reduction in IDO2 catalytic activity, whereas
the other SNP (Y359stop) generates a premature stop codon
abolishing activity completely.
9 It was recently described that
IDO2-reactive Tcells were present in peripheral blood of cancer
patients and that these Tcells were able to recognize and kill
tumor cells.
11 In the current study, we examined the association
between the presence of spontaneous IDO2-specific Tcells and
the functional status of the IDO2 protein based on genotyping of
the two IDO2 SNPs. Our data demonstrate that spontaneous
cytotoxic T-cell reactivity against IDO2 requires a full-length
IDO2 protein.
Results
Genotyping. To investigate the association between spontaneous
IDO2-specific T-cell responses and the functional status of the
IDO2 protein, we genotyped DNA from HLA-A2
+ individuals
for the two SNPs: Y359stop and R248W using RT-PCR and
sequencing. We genotyped 21 healthy donors, 12 malignant
melanoma patients, 5 renal cell carcinoma patients and 6 breast
cancer patients for the SNP Y359stop. For the SNP R248W we
genotyped 19 healthy donors, 12 malignant melanoma patients,
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5 renal cell carcinoma patients and 6 breast cancer patients. The
combined genotypes are shown in Table1. The number of
individuals found in the combined groups did not seem to be
independently distributed. Thus, some groups had a limited
number of individuals. In particular, no individuals were homo-
zygous on both SNPs for the stop/decreased activity alleles
(combined genotype of 359 stop/stop and 248 low/low) and just
2 out of 42 individuals had a genotype encoding a fully active
IDO2 protein (359 wt/wt and 248 wt/wt).
Association between IDO2 genotype and IDO2 specific
T-cell responses. ELISPOT assays were performed to detect
specific T cells against three IDO2-derived peptide epitopes:
IDO2273–281, IDO2354–362 and IDO2386–394. Positive T-cell
responses against the peptides were defined as . 50 spots/2  10
5
PBMC. We found that T-cell responses against the 3 IDO2
epitopes were restricted to individuals being SNP Y359stop
homozygous or heterozygous wildtype (359 wt/wt or 359 wt/
stop) (Fig.1A). Thus, we did not detect any responses in the
group with the 359 stop/stop genotype for any of the examined
epitopes. Individuals being homozygous Y359 wild type
(359 wt/wt) had a significantly higher number of responses
against peptide IDO2386–394 (located down-stream of the
Y359stop SNP) than individuals having a heterozygous wild type
(359 wt/stop) or homozygous stop (359 stop/stop) genotype
(p = 0.04). Furthermore we found a significant association
between the numbers of T-cell responses in each of the three
genotypes by comparing them in an ordered manner to the
number of responses (p = 0.04). Hence, more responses were
detected in the donors with the homozygous wildtype
(359 wt/wt) genotype than the heterozygous genotype
(359 wt/stop). Likewise, more responses were detected in the
donors with the heterozygous (359 wt/stop) genotype than the
homozygous stop (359 stop/stop) (Fig.1A).
T-cell responses against peptide IDO2273–281 (located up-
stream of the Y359stop SNP) were equally only found in
individuals being homozygous Y359 wild type or heterozygous.
Two T-cell responses out of 16 tested were detected against the
third epitope; IDO2354–362 (this peptide spans the position of
Y359stop SNP) and both were detected in individuals being
homozygous Y359 wildtype (359 wt/wt). However, more indivi-
duals need to be analyzed to firmly conclude on the association
between the IDO2 genotype and the T-cell responses against
this peptide.
For the SNP R248W the C genotype gives rise to the amino
acid Arginine (R) (248wt) whereas the T genotype gives rise to
the amino acid Tryptophan (W) (248low). We found that
7T-cell responses out of 28 tested (~25%) against the 3 IDO2
peptides were detected in the homozygous low group; 248 low/
low, 8 out of 49 tested (~16%) were found in the 248 wt/low
group, and 1 out of 17 tested (~5%) was detected in the
248 wt/wt group (Fig.1A).
Next, we investigated the association between IDO2 T-cell
responses and the combined genotype of the two IDO2 SNP
variants. As previously mentioned the number of individuals
found in the combined groups did not seem to be independently
distributed. Thus, only 2 out of 42 individuals were homozygous
for both functional alleles (248 wt/wt/359 wt/wt) (Fig.1B), and
no individuals were homozygous for the non-functional alleles
(248 low/low and 359 stop/stop) (data not shown).
Immune responses in healthy donors and cancer patients.
We analyzed the relevance of the measured T-cell responses in
healthy donors (n = 21) and cancer patients (n = 23) separately.
It seemed that the natural immunity against IDO2 was lower
in healthy individuals compared with cancer patients (Fig.2)
although one healthy donor (248 low/low, 359 wt/stop) had a
strong response against IDO2273–281.
Association between IDO2 genotype and virus specific T-cell
responses. To investigate whether the association between IDO2
genotype and specific T-cell responses has any relevance to T-cell
responses against alternative antigens, we performed direct
ELISPOT to detect T cells against the well characterized HLA-
A2 restricted peptide pp65 from CMV (NLVPMVATV) and the
peptide from BMLF1 from EBV (GLCTLVAML). The presence
of EBV specific T cells in the periphery did not seem to be
associated with IDO2 SNP genotype as specific T cells were
detected in all genotype groups (Fig.3). However, notably the
strongest CMV responses were detected in donors having a
homozygous wildtype (359 wt/wt) IDO2.
Table1. Distribution of Y359stop and R248W genotypes. The table shows
distribution of the Y359stop allele and R248W allele and the association of
the two. p value calculated by Spearman rank correlation
Y359stop R248W
359 wt/wt 21 (48%) 248 wt/wt 7 (17%)
359 wt/stop 17 (39%) 248 wt/low 23 (55%)
359 stop/stop 6 (14%) 248 low/low 12 (29%)
Combined genotypes 248 wt/wt 248 wt/low 248 low/low
359 wt/wt 2 13 6
359 wt/stop 2 8 6
359 stop/stop 3 2 0
p = 0.13
Figure1 (See opposite page). Association between IDO2 genotype and T-cell responses. (A) T-cell responses against 3 peptides from IDO2 (IDO2273–281,
IDO2354–362, IDO2386–394) as measured by indirect ELISPOT are shown for individuals grouped according to their SNP Y359stop (upper row) and SNP 248W
(lower row) genotype. Responses were only found in individuals having homozygous or heterozygous wildtype genotype (359 wt/wt or 359 wt/stop).
Homozygous 359 wild type Y/Y (wt/wt; upper left), heterozygous Y/STOP (wt/stop; upper middle) and homozygous STOP/STOP (stop/stop, upper right).
Homozygous R248 wild type R/R (wt/wt, lower left), heterozygous R/W (wt/low, lower middle) and homozygous W/W (low/low, lower right). (B) T-cell
responses against three peptides from IDO2 (IDO2273–281, IDO2354–362, IDO2386–394) are shown for individuals grouped according to their combined
genotype of the two polymorphic SNP variants. Two out of forty-two individuals were Y359 wt/wt – R248 wt/wt (upper left). None was Y359 stop/stop–
R248 low/low (data not shown).
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Figure1. For figure legend, see page 442.
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Discussion
Emerging evidence suggests that during cancer progression
activation of the IDO pathway might act as an important
modifier pathway for immune escape.
12 Small molecule inhibitors
of IDO and IDO2 heighten chemotherapeutic efficacy in mouse
models of cancer in a nontoxic fashion.
13 Hence, the targeting of
these proteins offers promising ways to broaden the combinatorial
attack on advanced cancers, where immune escape mechanisms
likely provide pivotal support. Furthermore, it was recently shown
that IDO2-specific Tcells were present in the peripheral blood
and that they were able to recognize and kill tumor cells.
11
Interestingly, the coding region of the human IDO2 gene
includes two nonsynonymous SNPs that strongly ablate enzyma-
tic activity. The use of IDO2 as a target in the clinic will be
restricted to patients having the active genotype. One SNP
(R248W) has been associated with a reduction in IDO2 catalytic
activity, whereas the other SNP (Y359stop) generates a premature
stop codon abolishing activity completely.
14
In the present study, we investigated the association between
a specific cellular immune response and the functional status of
the IDO2 protein as based on IDO2 SNP genotyping. Several
HLA-A2-restricted IDO2-derived T-cell epitopes have been
described. We examined the apparently most immunogenic
epitope IDO2273–281, which are located before the Y359stop
SNP, an additional epitope spanning the Y359stop SNP
(IDO2354–362) and finally an epitope IDO2386–394 located
down-stream the Y359stop SNP. We found that specific T cells
against the three different HLA-A2-restricted peptides from
IDO2 were restricted to individuals being either homozygous
or heterozygous wildtype for the Y359stop SNP (359 wt/wt or
359 wt/stop). No T-cell responses were detected in individuals
being homozygous for the 359 stop allele (359 stop/stop). Hence,
these findings suggest that the induction of IDO2-specific T cells
in peripheral blood requires the presence of a functional IDO2
protein and, consequently, is restricted to individuals that are
not homozygous for the stop codon. Furthermore, there was a
tendency of a higher number of T-cell responses within the
homozygous wildtype genotype when compared with the hetero-
zygous genotype. This could be due to a higher level of expression
of IDO2 in these individuals.
Interestingly, when looking at the other SNP (R248W) we
found that the immune responses seemed higher for the most
immunogenic IDO2-derived epitope (IDO2273–281) in indivi-
duals homozygous for the SNP allele (248 low) giving reduction
in IDO2 activity. Hence, spontaneous immune responses against
IDO2 depend on the generation of a functional target protein
but seem, in addition, to be associated with reduced enzymatic
activity of IDO2. This could suggest that the enzymatic activity
of IDO2 influences the systemic adaptive immune response
and, furthermore, that the immune suppressive effects of IDO2
expression in the target cells suppress the cytotoxic T-cell
responses generated against this cancer antigen.
We additionally analyzed the association between IDO2 geno-
type and T-cell responses toward virus antigens. The strongest
CMV responses were detected in donors who were homozygous
for the IDO2 359 wt/wt genotype, which could suggest a
correlation between IDO2 and CMV responses. Although this
needs to be verified, we have previously found that the presence
of IDO-specific T-cell responses correlated with the presence of
CMV-responses.
The number of IDO2-specific T-cell responses found in cancer
patients and healthy donors did not differ significantly although
responses appeared to be stronger among cancer patients. IDO2-
specific Tcells have been described to recognize and kill tumor
cells. IDO2 might—especially considering the immune suppres-
sive functions of IDO—be a useful target for anti-cancer
immunotherapeutic strategies. However, since the spontaneous
Figure2. T-cell responses against IDO2 in healthy donors vs. cancer patients. T-cell responses against peptides IDO2273–281 (left), IDO2354–362 (middle)
and IDO2386–394 (right) are shown for healthy donors (HD) and cancer patients (Cancer patients). T-cell immunity toward IDO2 was seemingly lower in
healthy donors compared with cancer patients.
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immune responses against IDO2, as described here, were
depending on the IDO2 genotype, the patient IDO genotype
might likewise influence the potential outcome of such clinical
measures.
Materials and Methods
Donors. Peripheral blood mononuclear cells (PBMC) were
collected from healthy individuals and cancer patients (renal cell
carcinoma, melanoma and breast cancer). Blood samples from
cancer patients were drawn a minimum of four weeks after
termination of any kind of anti-cancer therapy. The majority of
renal cell carcinoma patients had previously been treated with
IL-2 and INFa, most melanoma patients had received high
dose IL-2 and INFa, while the breast cancer patient was pre-
treated with several kinds of chemotherapy, (e.g., epirubicin,
docetaxel and cabecitabine), trastuzumab and/or endocrine
therapy. PBMC were isolated using lymphoprep separation,
HLA-typed (Department of Clinical Immunology, University
Hospital, Copenhagen, Denmark) and frozen in FCS with 10%
DMSO. Informed consent was obtained from the patients prior
to any of these measures.
Peptides. Three synthetic HLA-A2 restricted IDO2-derived
peptides were synthesized for ELISPOT (TAG Copenhagen,
Copenhagen, Denmark. IDO2273–281 (VLHAFDEFL),
IDO2354–362 (YLITAAAKA), IDO2386–394) and IDO2386–394
(AVMSFLKSV).Two HLA-A2 restricted virus peptides were used
in ELISPOT: CMV pp65 (NLVPMVATV) and EBV BMLF1
(GLCTLVAML).
ELISPOT assay. The ELISPOT assay was used to quantify
peptide-specific INFc releasing effector cells as described.
15 For
analyses of IDO2 specific T-cell responses, PBMC were
stimulated once in vitro with peptide prior to analysis as
described
16 to extend the sensitivity of the assay. After seven days
Figure3. IDO2 genotype and virus specific T-cell responses. T-cell responses against HLA-A2 restricted peptides from CMV (NLVPMVATV) and EBV
(GLCTLVAML) were detected by use of direct ELISPOT. The strongest CMV specific T-cell responses seemed to be in the genotype group homozygous 359
wild type (359 wt/wt). *In this donor the number of spots was estimated to be . 1,000.
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in culture in X-vivo15
TM (BioWhittaker) medium with 25 mg/ml
peptide and 20 U/ml IL-2 (PeproTech), cells were counted and
analyzed in ELISPOT. CMV and EBV-specific Tcells were
detected directly ex vivo with no prior stimulation and for these
analyses PBMC were thawn and rested overnight before being
counted and analyzed in ELISPOT. Briefly, nitrocellulose
bottomed 96-well plates (MultiScreen MAIP N45; Millipore)
were coated overnight with INFc capture mAb (Mabtech). The
wells were washed, blocked by X-vivo15 medium. Cells were
added in duplicates at different cell concentrations, with (experi-
mental wells) or without (control wells) 5 mg/ml peptide. The
plates were incubated overnight. The following day, medium was
discarded and the wells were washed prior to addition of
appropriate biotinylated secondary mAb (Mabtech). The plates
were incubated at room temperature (RT) for 2 h, washed, and
Avidin-enzyme conjugate (AP-Avidin; Calbiochem/Invitrogen
Life Technologies) was added to each well. Plates were incubated
at RT for 1 h and the enzyme substrate NBT/BCIP (Invitrogen
Life Technologies) was added to each well and incubated at RT
for 5–10 min. Upon the emergence of dark purple spots, the
reaction was terminated by washing with tap water. The spots
were counted using the ImmunoSpot Series 2.0 Analyzer (CTL
Analyzers). For indirect ELISPOT: positive responses were
defined as (mean number of spots in experimental wells) - (mean
number of spots in control wells) . 50 spots/2  10
5 PBMC as
previously.
11 In general, direct ELISPOT did not give any
background spots.
Genotyping. Genotyping was performed by polymerase chain
reaction (PCR) and subsequent sequencing. We isolated genomic
DNA using the NucleoSpinG tissue kit (Macherey-Nagel,
Germany) and performed PCR amplifications of the Y359Stop
(forward primer: 5'-TAGAAGACATCCACTCAGCACC-3',
reverse primer: 5'-CGTGGGTGAAGGATTGACTC-3') and
R248W (forward primer: 5'-TGCAGCTTTCATTCCAGG
TCTCCA-3' and the reverse primer: 5'-CTGAGAGTGGAT
CCCTAGCAAGAGT-3') polymorphisms.
9 Amplifications were
performed in a total volume of 15 ml containing 1 PCR buffer
[50 mM KCl, 20 mM Tris pH 8.4, 2.0 mM MgCl2, 0.2 mM
cresol red, 12% sucrose, 0.005% (wt/v) BSA (Boehringer-
Mannheim)], 5 pmol of each primer, 40 mM dNTPs
(Pharmacia LKB, Sweden) and 1.25 U of AmpliTaq poly-
merase (Perkin Elmer Cetus Corporation). Conditions used for
amplification were 40 cycles at 94°C for 2 min, 94°C for 30 sec,
65°C for 60 sec, and 72°C for 60 sec. Sequencing was performed
using the BigDye
1 Terminator v3.1 Cycle Sequencing Kit
(sequencing primer for Y359stop: 5'-ACGTGGGTGAAGGAT
TGACTC-3' and R248W: 5'-TGCAGCTTTCATTCCAGG
TCTCCA-3' (forward primer)) and analyzed by a 3500 Genetic
Analyzer (Applied Biosystems).
Statistics. Fisher’s exact test was used for comparing categorical
variable ie genotypes and ELISPOT responses. When analyzing
genotype as an ordinal variable spearman rank correlation was
used.
Due to the sample size exact or Monte Carlo methods were
used for calculating p values.
All p values were two-sided and p-values below 0.05 were
considered significant. All calculation were done with R statistical
software version 2.12.1 (R Foundation for Statistical Software,
2011). Calculations using exact and Monte Carlo methods were
done with the “coin” package.
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